




Instance: composition-en-5f2f3f0c1c43271a861dd5210ff699a4
InstanceOf: CompositionUvEpi
Title: "Composition for opzelura Package Leaflet"
Description:  "Composition for opzelura Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp5f2f3f0c1c43271a861dd5210ff699a4)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - opzelura"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Opzelura is and what it is used for  </li>
<li>What you need to know before you use Opzelura </li>
<li>How to use Opzelura </li>
<li>Possible side effects  </li>
<li>How to store Opzelura </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What opzelura is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What opzelura is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opzelura contains the active substance ruxolitinib. It belongs to a group of medicines called Janus 
kinase inhibitors. </p>
<p>Opzelura is used on the skin to treat vitiligo with facial involvement in adults and adolescents from 
12 years. Vitiligo is an autoimmune disease, where the body s immune system attacks the cells that 
produce the skin pigment melanin. This causes a loss of melanin, leading to patches of pale pink or 
white skin. In vitiligo, ruxolitinib reduces the immune system s activity against the melanin-producing 
cells, allowing the skin to produce pigment and regain its normal colour.  </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take opzelura"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take opzelura"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not use Opzelura 
- if you are allergic to ruxolitinib or any of the other ingredients of this medicine (listed in 
section 6). 
- if you are pregnant or breastfeeding. </p>
<p>Warnings and precautions<br />
Talk to your doctor or pharmacist before using Opzelura. </p>
<p>Opzelura is not for use on the lips, in the eyes, mouth or vagina. If cream accidentally gets into these 
areas, thoroughly wipe off and/or rinse off the cream with water. </p>
<p>Children under 12 years 
Do not give Opzelura to children younger than 12 years because it has not been studied in this age 
group.  </p>
<p>Other medicines and Opzelura 
Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines. </p>
<p>Using Opzelura at the same time as other medicines on the affected skin is not recommended, as it has 
not been studied. </p>
<p>After applying Opzelura, wait at least 2 hours before applying other medicines, sunscreen or body 
creams/oils to the same skin area. </p>
<p>Pregnancy and breast-feeding 
Opzelura should not be used by pregnant or breast-feeding women as this has not been investigated. If 
you are a woman of childbearing age, you should use an effective contraception during treatment and 
during 4 weeks after applying Opzelura for the last time. </p>
<p>It is not known if ruxolitinib passes into breast milk after applying it to the skin. The effects of this 
medicine in breastfed infants are unknown; therefore, Opzelura should not be used if you are 
breast-feeding or planning to breastfeed. You may start breast-feeding approximately four weeks after 
applying Opzelura for the last time. </p>
<p>Driving and using machines 
Opzelura is unlikely to have an effect on your ability to drive and use machines. </p>
<p>Opzelura contains propylene glycol, cetyl alcohol, stearyl alcohol, methyl parahydroxybenzoate, 
propyl parahydroxybenzoate and butylated hydroxytoluene 
- This medicine contains 150 mg propylene glycol (E1520) in each gram of cream, which may 
cause skin irritation. 
- Cetyl alcohol and stearyl alcohol may cause local skin reactions (e.g. contact dermatitis). 
- Methyl parahydroxybenzoate (E218) and propyl parahydroxybenzoate may cause allergic 
reactions (possibly delayed). 
- Butylated hydroxytoluene (E321) may cause local skin reactions (e.g. contact dermatitis), or 
irritation to the eyes and mucous membranes. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take opzelura"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take opzelura"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always use this medicine exactly as your doctor or pharmacist has told you. Check with your doctor 
or pharmacist if you are not sure. </p>
<p>Recommended dose 
- Apply a thin layer of cream twice daily to affected areas of your skin. Wait at least 8 hours 
between applications. 
- The cream should not be used on more than 10% (one tenth) of your body. This surface area 
represents the equivalent to ten times the palm of one hand with the five fingers. </p>
<p>Method of administration 
- This medicine is for use on the skin only.<br />
- Do not apply to skin surfaces other than the ones instructed by your doctor. The medicine should 
be used at the smallest skin area necessary. 
- Wash your hands after applying this medicine, unless you are treating your hands. If someone 
applies this medicine to you, they should wash their hands after application. 
- Avoid washing treated skin for at least 2 hours after application of Opzelura. </p>
<p>Duration of use 
Your doctor will decide how long you should use the cream for. 
A minimum duration of 6 months is recommended but satisfactory treatment may require over 
12 months. If you achieve satisfactory repigmentation of treated areas, consult your doctor to discuss if 
treatment of those areas could be stopped. Consult your doctor if you experience loss of 
repigmentation after stopping treatment. </p>
<p>Do not use more than two 100 gram tubes a month.<br />
If you use more Opzelura than you should 
Wipe off the excess cream if this occurs. </p>
<p>If you forget to use Opzelura 
If you forget to apply the cream at the scheduled time, do it as soon as you remember, then continue 
your normal dosing schedule. However, if the next scheduled dose is due within 8 hours, skip the 
missed dose. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>The following side effects have been reported with Opzelura: 
Common (may affect up to 1 in 10 people) 
- acne at application site </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects 
not listed in this leaflet. You can also report side effects directly via the national reporting system 
listed in Appendix V. By reporting side effects, you can help provide more information on the safety 
of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store opzelura"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store opzelura"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the tube and carton after EXP. The 
expiry date refers to the last day of that month. </p>
<p>Do not store above 30  C. </p>
<p>Once the tube has been opened, use the cream within 6 months but not after the expiry date.  </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Opzelura contains<br />
- The active substance is ruxolitinib. 
One gram of cream contains 15 mg of ruxolitinib. 
- The other ingredients are butylated hydroxytoluene (E321), cetyl alcohol, dimeticone (E900), 
disodium edetate (E385), glyceryl stearate, paraffin (E905), macrogol, medium chain 
triglycerides, methyl parahydroxybenzoate (E218), phenoxyethanol, polysorbate 20 (E432), 
propylene glycol (E1520), propyl parahydroxybenzoate, purified water, stearyl alcohol, 
xanthan gum (E415). </p>
<p>See section 2  Opzelura contains propylene glycol, cetyl alcohol, stearyl alcohol, methyl 
parahydroxybenzoate, propyl parahydroxybenzoate and butylated hydroxytoluene . </p>
<p>What Opzelura looks like and contents of the pack 
Opzelura cream is coloured white to off-white, supplied in a tube containing 100 g cream. There is one 
tube per carton. </p>
<p>Marketing Authorisation Holder and Manufacturer 
Incyte Biosciences Distribution B.V. 
Paasheuvelweg 1105 BP Amsterdam 
Netherlands </p>
<p>This leaflet was last revised in  </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-5f2f3f0c1c43271a861dd5210ff699a4
InstanceOf: CompositionUvEpi
Title: "Composition for opzelura Package Leaflet"
Description:  "Composition for opzelura Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp5f2f3f0c1c43271a861dd5210ff699a4)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - opzelura"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse 
2. Det skal du vide, før du begynder at bruge Opzelura 
3. Sådan skal du bruge Opzelura 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What opzelura is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What opzelura is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opzelura indeholder det aktive stof ruxolitinib. Det tilhører en gruppe lægemidler, der kaldes 
januskinasehæmmere. </p>
<p>Opzelura anvendes på huden som behandling af vitiligo med involvering af ansigtet hos voksne og 
unge fra 12 år. Vitiligo er en autoimmun sygdom, hvor kroppens immunforsvar angriber de celler, der 
producerer hudpigmentet melanin. Dette medfører tab af melanin, så der opstår pletter af svagt lyserød 
eller hvid hud. Ruxolitinib virker mod vitiligo ved at reducere immunforsvarets aktivitet mod de 
melaninproducerende celler, så huden kan producere pigment og genvinde sin normale farve. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take opzelura"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take opzelura"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug ikke Opzelura 
- hvis du er allergisk over for ruxolitinib eller et af de øvrige indholdsstoffer i Opzelura (angivet i 
afsnit 6). 
- hvis du er gravid eller ammer. </p>
<p>Advarsler og forsigtighedsregler 
Kontakt lægen eller apotekspersonalet, før du bruger Opzelura. </p>
<p>Opzelura må ikke bruges på læberne, i øjnene, i munden eller i skeden. Hvis der ved et uheld kommer 
creme disse steder, skal du tørre cremen grundigt af og/eller skylle cremen af med vand. </p>
<p>Børn under 12 år 
Giv ikke Opzelura til børn under 12 år, da det ikke er undersøgt i denne aldersgruppe. </p>
<p>Brug af andre lægemidler sammen med Opzelura 
Fortæl det altid til lægen eller apotekspersonalet, hvis du bruger andre lægemidler, for nylig har brugt 
andre lægemidler eller planlægger at bruge andre lægemidler. </p>
<p>Det frarådes at bruge Opzelura på samme tid som andre lægemidler på det berørte hudområde, da det 
ikke er blevet undersøgt. </p>
<p>Når du har påført Opzelura, skal du vente i mindst 2 timer, inden du påfører andre lægemidler, 
solcreme eller andre cremer/olier på det samme hudområde. </p>
<p>Graviditet og amning 
Opzelura må ikke bruges af gravide kvinder eller kvinder, der ammer, da dette ikke er blevet 
undersøgt. Hvis du er en kvinde i den fødedygtige alder, skal du anvende effektiv prævention under 
behandlingen og i 4 uger efter, at du har påført Opzelura for sidste gang. </p>
<p>Det vides ikke, om ruxolitinib går over i modermælken, når det er blevet påført på huden. 
Virkningerne af dette lægemiddel hos ammede spædbørn er ukendt, og derfor må du ikke bruge 
Opzelura, hvis du ammer eller planlægger at amme. Du kan begynde at amme ca. fire uger efter, at du 
har påført Opzelura for sidste gang. </p>
<p>Trafik og arbejdssikkerhed 
Det er ikke sandsynligt, at Opzelura vil påvirke din evne til at køre og bruge maskiner. </p>
<p>Opzelura indeholder propylenglycol, cetylalkohol, stearylalkohol, methylparahydroxybenzoat, 
propylparahydroxybenzoat og butylhydroxytoluen 
- Dette lægemiddel indeholder 150 mg propylenglycol (E1520) pr. gram creme, som kan give 
irritation af huden. 
- Cetylalkohol og stearylalkohol kan give lokalt hududslæt (f.eks. kontakteksem). 
- Methylparahydroxybenzoat (E218) og propylparahydroxybenzoat kan give allergiske reaktioner 
(kan optræde efter behandlingen). 
- Butylhydroxytoluen (E321) kan give lokalt hududslæt (f.eks. kontakteksem) og irritation af øjne 
og slimhinder. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take opzelura"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take opzelura"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Brug altid lægemidlet nøjagtigt efter lægens eller apotekspersonalets anvisning. Er du i tvivl, så spørg 
lægen eller apotekspersonalet. </p>
<p>Anbefalet dosis 
- Påfør et tyndt lag creme to gange om dagen på de berørte områder af din hud. Der skal gå mindst 
8 timer mellem påføringerne. 
- Cremen må ikke bruges på mere end 10 % (en tiendedel) af din krop. Dette område svarer til ca. ti 
gange én hånd inklusive de fem fingre. </p>
<p>Påføring 
- Dette lægemiddel må kun anvendes på huden. 
- Du må ikke påføre det på andre hudoverflader end dem, som din læge har fortalt dig, du skal 
påføre cremen på. Lægemidlet skal påføres på et så lille hudområde som muligt. 
- Vask hænder efter brug af dette lægemiddel, medmindre du behandler dine hænder. Hvis en anden 
person påfører cremen på dig, skal denne person vaske hænder efter påføring. 
- Undgå at vaske den behandlede hud i mindst 2 timer efter påføring af Opzelura. </p>
<p>Anvendelsesperiode 
Din læge vil beslutte, hvor længe du skal anvende cremen. 
Mindst 6 måneder anbefales, men det kan tage over 12 måneder at opnå et tilfredsstillende resultat. 
Hvis du opnår tilfredsstillende repigmentering af de behandlede områder, skal du tale med lægen om, 
hvorvidt du kan stoppe behandlingen på disse områder. Tal med lægen, hvis du oplever tab af 
repigmentering efter ophør af behandlingen. </p>
<p>Brug ikke mere end to tuber a 100 gram om måneden. </p>
<p>Hvis du har brugt for meget Opzelura 
Tør den overskydende creme af, hvis dette sker. </p>
<p>Hvis du har glemt at bruge Opzelura 
Hvis du glemmer at påføre cremen på det planlagte tidspunkt, skal du gøre det, så snart du kommer i 
tanke om det. Fortsæt derefter med den normale plan. Hvis der er mindre end 8 timer til den næste 
planlagte dosis, skal du dog springe den glemte dosis over. </p>
<p>Spørg lægen eller apotekspersonalet, hvis der er noget, du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Følgende bivirkninger er blevet indberettet med Opzelura: 
Almindelige (kan forekomme hos op til 1 ud af 10 personer) 
- akne på påføringsstedet </p>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge eller apotekspersonalet. Dette gælder også 
mulige bivirkninger, som ikke er medtaget i denne indlægsseddel. Du eller dine pårørende kan også 
indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i 
Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information 
om sikkerheden af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store opzelura"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store opzelura"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Brug ikke lægemidlet efter den udløbsdato, der står på tuben og æsken efter EXP. Udløbsdatoen er den 
sidste dag i den nævnte måned. </p>
<p>Må ikke opbevares ved temperaturer over 30 °C. </p>
<p>Når tuben er åbnet, skal cremen bruges inden for 6 måneder, dog ikke senere end udløbsdatoen. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe lægemiddelrester. Af hensyn til miljøet må du 
ikke smide lægemiddelrester i afløbet, toiletter eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opzelura indeholder:</p>
<ul>
<li>Aktivt stof: ruxolitinib. 
Ét gram creme indeholder 15 mg ruxolitinib. </li>
<li>Øvrige indholdsstoffer: butylhydroxytoluen (E321), cetylalkohol, dimeticon (E900), 
dinatriumedetat (E385), glycerylstearat, paraffin (E905), macrogol, triglycerider, 
middelkædelængde, methylparahydroxybenzoat (E218), phenoxyethanol, polysorbat<br />
(E432), propylenglycol (E1520), propylparahydroxybenzoat, vand, renset, stearylalkohol, 
xanthangummi (E415). </li>
</ul>
<p>Se afsnit 2, "Opzelura indeholder propylenglycol, cetylalkohol, stearylalkohol, 
methylparahydroxybenzoat, propylparahydroxybenzoat og butylhydroxytoluen". </p>
<p>Udseende og pakningsstørrelser 
Opzelura er en hvid til offwhite creme, som leveres i en tube med 100 g creme. Der er én tube i hver 
æske. </p>
<p>Indehaver af markedsføringstilladelsen og fremstiller 
Incyte Biosciences Distribution B.V. 
Paasheuvelweg 1105 BP Amsterdam 
Holland </p>
<p>Denne indlægsseddel blev senest ændret </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-5f2f3f0c1c43271a861dd5210ff699a4
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for opzelura Package Leaflet for language en"
Description: "ePI document Bundle for opzelura Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-5f2f3f0c1c43271a861dd5210ff699a4"
* entry[0].resource = composition-en-5f2f3f0c1c43271a861dd5210ff699a4

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp5f2f3f0c1c43271a861dd5210ff699a4"
* entry[=].resource = mp5f2f3f0c1c43271a861dd5210ff699a4
                            
                    
Instance: bundlepackageleaflet-da-5f2f3f0c1c43271a861dd5210ff699a4
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for opzelura Package Leaflet for language da"
Description: "ePI document Bundle for opzelura Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-5f2f3f0c1c43271a861dd5210ff699a4"
* entry[0].resource = composition-da-5f2f3f0c1c43271a861dd5210ff699a4

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp5f2f3f0c1c43271a861dd5210ff699a4"
* entry[=].resource = mp5f2f3f0c1c43271a861dd5210ff699a4
                            
                    



Instance: mp5f2f3f0c1c43271a861dd5210ff699a4
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Opzelura 15 mg/g cream"
Description: "Opzelura 15 mg/g cream"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "EU/1/23/1726/001"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Opzelura 15 mg/g cream"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 5f2f3f0c1c43271a861dd5210ff699a4ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "opzelura"

* status = #current
* mode = #working

* title = "List of all ePIs associated with opzelura"

* subject = Reference(mp5f2f3f0c1c43271a861dd5210ff699a4)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#opzelura "opzelura"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-5f2f3f0c1c43271a861dd5210ff699a4) // opzelura en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-5f2f3f0c1c43271a861dd5210ff699a4) // opzelura da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-5f2f3f0c1c43271a861dd5210ff699a4
InstanceOf: List

* insert 5f2f3f0c1c43271a861dd5210ff699a4ListRuleset
    